Journal
CELL RESEARCH
Volume 27, Issue 1, Pages 74-95Publisher
INST BIOCHEMISTRY & CELL BIOLOGY
DOI: 10.1038/cr.2016.157
Keywords
dendritic cell; immunotherapy
Categories
Funding
- Cancer Research Institute
- Melanoma Research Alliance
- NIH [AI044628, CA180913, AI081848]
- NATIONAL CANCER INSTITUTE [R01CA180913] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI044628, R01AI044628, R01AI081848] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available